Aspire Biopharma Warrant
ASBPW
36 hedge funds and large institutions have $7.27M invested in Aspire Biopharma Warrant in 2022 Q2 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$228K |
| 2 |
SCM
Saba Capital Management
New York
|
+$214K |
| 3 |
LA
Linden Advisors
New York
|
+$196K |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$146K |
| 5 |
SC
Sculptor Capital
New York
|
+$109K |
Top Sellers
ASBPW Hedge Fund Activity: Q2 2022 in Review
36 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q2 2022, worth a combined $7.27M.
Buyers outnumbered sellers: 36 funds opened new ASBPW positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $228K.
- 36 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q2 2022, up from 0 in Q1 2022.
- Funds reported $7.27M of Aspire Biopharma Warrant stock for Q2 2022.
- 36 funds opened new Aspire Biopharma Warrant positions in Q2 2022 and 0 closed out, a net change of +36 holders.
- The largest Aspire Biopharma Warrant buyer in Q2 2022 was Adage Capital Partners, an estimated $228K added.
Based on aggregated 13F filings for Q2 2022.